Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results

References

• Bedimo RJ, Drechsler H, Jain M, et al. (2014). The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One 9:e106221
   PubMed Web of Science ®Google Scholar
• Bergshoeff AS, Fraaij PL, Ndagijimana J, et al. (2005). Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J Acquir Immune Defic Syndr 39:63–8
   PubMed Web of Science ®Google Scholar
• Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. (2011). Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143–51
   PubMed Web of Science ®Google Scholar
• Boffito M, Arnaudo I, Raiteri R, et al. (2002). Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 16:2081–3
   PubMed Web of Science ®Google Scholar
• Bouazza N, Urien S, Blanche S, et al. (2014). Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Pediatr Infect Dis J 33:e213–18
   Google Scholar
• Breilh D, Pellegrin I, Rouzes A, et al. (2004). Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305–10
   PubMed Web of Science ®Google Scholar
• Charpentier C, Jenabian MA, Piketty C, et al. (2011). Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scand J Infect Dis 43:373–9
   PubMed Web of Science ®Google Scholar
• Chong H, Yao X, Zhang C, et al. (2012). Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 7:e32599
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Molina JM, Cahn P, et al. (2012). Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 60:33–42
   PubMed Web of Science ®Google Scholar
• Dolgin E. (2014). Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med 20:323–4
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. (2013). Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 208:32–9
   PubMed Web of Science ®Google Scholar
• Gupta RK, Jordan MR, Sultan BJ, et al. (2012). Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380:1250–8
   PubMed Web of Science ®Google Scholar
• Hosseinipour MC, Gupta RK, Van Zyl G, et al. (2013). Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis 207:S49–56
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. (1998). Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–91
   PubMed Web of Science ®Google Scholar
• Hurst M, Faulds D. (2000). Lopinavir. Drugs 60:1371–9; discussion 1380-1
   PubMed Web of Science ®Google Scholar
• Kilby JM, Hopkins S, Venetta TM, et al. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302–7
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O'hearn M, et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–85
   PubMed Web of Science ®Google Scholar
• Masquelier B, Breilh D, Neau D, et al. (2002). Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 46:2926–32
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H, et al. (2008). Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Aids 22:1389–97
   PubMed Web of Science ®Google Scholar
• Patel IH, Zhang X, Nieforth K, et al. (2005). Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 44:175–86
   PubMed Web of Science ®Google Scholar
• Rabi SA, Laird GM, Durand CM, et al. (2013). Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 123:3848–60
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. (2011). Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53:807–16
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. (2011). Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204:1191–201
   PubMed Web of Science ®Google Scholar
• Tashima K, Crofoot G, Tomaka FL, et al. (2014). Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther 11:39
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry. (2015). Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf
   Google Scholar
• Wilkin A, Pozniak AL, Morales-Ramirez J, et al. (2012). Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 28:437–46
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2012). WHO HIV drug resistance report—2012.Geneva:World Health Organization
   Google Scholar
• Wu H, Yao C, Lu R, et al. (2012). Albuvirtide, the first long-acting HIV-1 fusion inhibitor, suppressed viral replication in HIV infected adults. In: The Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2012 Sep 9–12; San Francisco, USA. Paper H-554
   Google Scholar
• Xie D, Yao C, Wang L, et al. (2010). An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191–6
   PubMed Web of Science ®Google Scholar
• Zhang H, Jin R, Yao C, et al. (2016). Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther 13:8
   PubMed Web of Science ®Google Scholar